Cabaletta Bio (CABA) Return on Capital Employed (2019 - 2025)
Cabaletta Bio's quarterly Return on Capital Employed came in at 135.34% in Q4 2025, down 6069.0% year-on-year from 2.27% in Q4 2024, and down 33.66% quarter-over-quarter from 101.25% in Q3 2025.
Cabaletta Bio has reported Return on Capital Employed for 7 years, with the latest figure at 135.34% in Q4 2025.
- For the quarter ending Q4 2025, Return on Capital Employed fell 6069.0% year-over-year to 135.34%; the trailing twelve-month figure through Dec 2025 stood at 135.34% (down 6069.0% YoY), and the FY2025 full-year result was 137.89%, down 7280.0% from the prior year.
- Return on Capital Employed for Q4 2025 stood at 135.34%, down from 101.25% in the prior quarter.
- The five-year high for Return on Capital Employed was 33.31% in Q1 2021, with the low at 135.34% in Q4 2025.
- Average Return on Capital Employed over 5 years is 59.44%, with a median of 49.14% recorded in 2024.
- Year-over-year, Return on Capital Employed soared 2015 bps in 2024 and sank 6069 bps in 2025.
- Tracing CABA's Return on Capital Employed over 5 years: stood at 39.89% in 2021, then sank by 43 bps to 57.09% in 2022, then soared by 34 bps to 37.81% in 2023, then tumbled by 97 bps to 74.65% in 2024, then slumped by 81 bps to 135.34% in 2025.
- The last three Return on Capital Employed figures came in at 135.34% (Q4 2025), 101.25% (Q3 2025), and 97.78% (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Cabaletta Bio | 194.84 Mn | 61.24 Mn | - | -135.34% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -135.34% |
| Sep 30, 2025 | -101.25% |
| Jun 30, 2025 | -97.78% |
| Mar 31, 2025 | -95.14% |
| Dec 31, 2024 | -74.65% |
| Sep 30, 2024 | -60.89% |
| Jun 30, 2024 | -47.44% |
| Mar 31, 2024 | -37.43% |
| Dec 31, 2023 | -37.81% |
| Sep 30, 2023 | -40.28% |
| Jun 30, 2023 | -44.94% |
| Mar 31, 2023 | -57.58% |
| Dec 31, 2022 | -57.09% |
| Sep 30, 2022 | -56.82% |
| Jun 30, 2022 | -50.83% |
| Mar 31, 2022 | -43.87% |
| Dec 31, 2021 | -39.89% |
| Sep 30, 2021 | -38.39% |
| Jun 30, 2021 | -38.03% |
| Mar 31, 2021 | -33.31% |
| Dec 31, 2020 | -29.92% |
| Sep 30, 2020 | -25.18% |
| Jun 30, 2020 | -21.05% |
| Mar 31, 2020 | -16.74% |
| Dec 31, 2019 | -17.78% |